Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC

Rhea-AI Summary

Revelation Biosciences Inc. (NASDAQ: REVB) announced that CEO James Rolke will present a corporate overview at the 2022 Virtual Growth Conference from March 28-30, 2022. The company focuses on developing immunologic-based therapies for disease prevention and treatment, including its lead candidate REVTx-99a, designed to combat respiratory viruses like SARS-CoV-2 and influenza. Additionally, Revelation is developing diagnostic solutions such as REVDx-501 for home use to detect respiratory infections. For details, visit www.RevBiosciences.com.

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will present a corporate overview at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

Sign up here to access the presentation

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99a, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99b is being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99a and REVTx-99b. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.

For more information on Revelation, please visit www.RevBiosciences.com.

Company Contacts

Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.
Email: svedrick@revbiosciences.com

and

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

FAQ

What is the focus of Revelation Biosciences Inc.?

Revelation Biosciences Inc. focuses on developing immunologic-based therapies for the prevention and treatment of diseases.

When will Revelation Biosciences present at the Virtual Growth Conference?

Revelation Biosciences will present from March 28-30, 2022, at the Virtual Growth Conference.

What is REVTx-99a developed by Revelation Biosciences?

REVTx-99a is an intranasal immunomodulator aimed at preventing or treating infections from respiratory viruses, including SARS-CoV-2.

What is REVDx-501 used for?

REVDx-501 is a rapid home-use diagnostic tool for detecting respiratory viral infections.

What are the company’s other product candidates?

In addition to REVTx-99a, Revelation is developing REVTx-99b for allergic rhinitis and REVTx-200 as a vaccination adjunct.

How can I access the presentation by Revelation Biosciences?

You can sign up to access the presentation at the Virtual Growth Conference on their website.